Leerink Partnrs Estimates Compugen FY2025 Earnings

Compugen Ltd. (NASDAQ:CGEN - Free Report) - Stock analysts at Leerink Partnrs issued their FY2025 EPS estimates for shares of Compugen in a research report issued on Monday, May 19th. Leerink Partnrs analyst D. Graybosch expects that the biotechnology company will post earnings of ($0.41) per share for the year. The consensus estimate for Compugen's current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Compugen's Q4 2025 earnings at ($0.11) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.34) EPS.

Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Monday, May 19th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.02). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The business had revenue of $2.28 million for the quarter, compared to analyst estimates of $3.70 million. During the same quarter in the prior year, the company earned ($0.08) earnings per share.

Separately, Wall Street Zen cut shares of Compugen from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Compugen Price Performance

Compugen stock traded down $0.02 during trading hours on Thursday, hitting $1.44. The company had a trading volume of 99,293 shares, compared to its average volume of 369,568. The firm has a market cap of $128.06 million, a PE ratio of 71.50 and a beta of 2.61. Compugen has a one year low of $1.13 and a one year high of $2.66. The firm has a 50-day moving average of $1.40 and a 200 day moving average of $1.68.

Institutional Investors Weigh In On Compugen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Compugen by 15.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 317,500 shares of the biotechnology company's stock worth $486,000 after acquiring an additional 43,165 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Compugen in the 4th quarter valued at approximately $103,000. Oppenheimer & Co. Inc. grew its stake in Compugen by 187.3% in the 4th quarter. Oppenheimer & Co. Inc. now owns 55,602 shares of the biotechnology company's stock valued at $85,000 after buying an additional 36,252 shares in the last quarter. Commonwealth Equity Services LLC purchased a new position in Compugen in the 4th quarter valued at approximately $32,000. Finally, Marshall Wace LLP grew its stake in Compugen by 84.9% in the 4th quarter. Marshall Wace LLP now owns 88,169 shares of the biotechnology company's stock valued at $135,000 after buying an additional 40,494 shares in the last quarter. 12.22% of the stock is owned by institutional investors.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.